Status of research and development of vaccines for chikungunya (Q40736589)

23 September 2017

Status of research and development of vaccines for chikungunya (English)

1 reference

23 September 2017

0 references

2

0 references

David W C Beasley

series ordinal

4

object named as

David W C Beasley

1 reference

23 September 2017

Claire Smalley

1

1 reference

PubMed ID

27026149

23 September 2017

Charles B Chesson

series ordinal

3

1 reference

PubMed ID

27026149

23 September 2017

language of work or name

English

0 references

publication date

26 March 2016

1 reference

23 September 2017

1 reference

23 September 2017

34

1 reference

23 September 2017

26

1 reference

23 September 2017

2976-2981

1 reference

Biology and pathogenesis of chikungunya virus

23 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.076

Chikungunya virus and prospects for a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.076

Reemergence of chikungunya virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.076

The Chikungunya epidemic on La Réunion Island in 2005-2006: a cost-of-illness study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.076

Dengue and other common causes of acute febrile illness in Asia: an active surveillance study in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.076

Chikungunya infection in India: results of a prospective hospital based multi-centric study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.076

High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.076

Control of immunopathology during chikungunya virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.076

Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.076

Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.076

Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.076

Do we need a vaccine against chikungunya?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.076

Therapeutics and vaccines against chikungunya virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.076

Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.076

Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.076

10.1016/J.VACCINE.2016.03.076

7 January 2021

Identifiers

DOI

1 reference

23 September 2017

1 reference

PubMed ID

27026149